RxDoctor Payments Data

Lawrence Kramer, MD

Pulmonary Disease · Watertown, NYNPI 1427001619

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 28 payments — averaging $44.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$869
  • AstraZeneca$98
  • Boehringer Ingelheim$61
  • Regeneron Healthcare Solutions, Inc.$37
  • Fisher & Paykel Healthcare Inc$35
  • GSK$29
  • plus $107 from 5 others

What the payments were for

  • Travel & lodging$69156%
  • Food & beverage$52843%
  • Education$161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 50th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$65,314
Medicare patients
497
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter293$332,268
Breo ElliptaFluticasone/Vilanterol344$235,168
Advair HfaFluticasone Propion/Salmeterol152$116,441
Incruse ElliptaUmeclidinium Bromide185$98,845
Breztri AerosphereBudesonide/Glycopyr/Formoterol67$86,488
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr111$81,657
Spiriva RespimatTiotropium Bromide83$81,310
Arnuity ElliptaFluticasone Furoate140$57,723
SymbicortBudesonide/Formoterol Fumarate97$40,216
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate91$36,825
Stiolto RespimatTiotropium Br/Olodaterol Hcl50$32,651
Fluticasone-SalmeterolFluticasone Propion/Salmeterol135$26,316
Combivent RespimatIpratropium/Albuterol Sulfate30$22,362
Albuterol Sulfate HfaAlbuterol Sulfate572$20,753
Fluticasone-VilanterolFluticasone/Vilanterol41$17,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$29$805,6611,073 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$98$139,822175 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$61$136,323163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →